# Cephalon clinical trials: 75 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 75 trials with Cephalon as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Cephalon: 75 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cephalon

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 75
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 75, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 11, 2012 | NCT01596673 | A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users | Cephalon | Phase 1 | Completed | Drug Abuse | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01596673) |
| March 27, 2012 | NCT01563601 | Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in... | Cephalon | Phase 3 | Withdrawn | Extensive-stage Small Cell Lung Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01563601) |
| July 22, 2011 | NCT01400854 | Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability | Cephalon | Observational | Completed | Cancer, Pain | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01400854) |
| May 2, 2011 | NCT01345357 | Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | Cephalon | Phase 1 | Completed | Solid Tumors or Mantle Cell Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01345357) |
| March 21, 2011 | NCT01319279 | A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function... | Cephalon | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01319279) |
| March 21, 2011 | NCT01319266 | A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and... | Cephalon | Phase 1 | Completed | Renal Impairment | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01319266) |
| February 28, 2011 | NCT01305408 | Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression... | Cephalon | Phase 3 | Completed | Depression | 399 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01305408) |
| November 15, 2010 | NCT01240876 | Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of... | Cephalon | Phase 1/2 | Completed | Sciatica | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01240876) |
| July 12, 2010 | NCT01159873 | Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women | Cephalon | Phase 1 | Terminated | Bone Loss, Osteoporosis | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01159873) |
| May 12, 2010 | NCT01121536 | Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With... | Cephalon | Phase 3 | Terminated | Depression | 867 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01121536) |
| April 22, 2010 | NCT01108341 | Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients... | Cephalon | Phase 2 | Completed | Non-Hodgkin's Lymphoma (NHL) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01108341) |
| March 4, 2010 | NCT01080807 | Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder | Cephalon | Phase 4 | Completed | Excessive Sleepiness | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01080807) |
| February 23, 2010 | NCT01073163 | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent... | Cephalon | Phase 3 | Completed | Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01073163) |
| February 22, 2010 | NCT01072929 | A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With... | Cephalon | Phase 3 | Completed | Depression | 433 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01072929) |
| February 22, 2010 | NCT01072630 | Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With... | Cephalon | Phase 3 | Completed | Depression | 492 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01072630) |
| December 2, 2009 | NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed... | Cephalon | Phase 1/2 | Terminated | Multiple Myeloma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01023880) |
| June 15, 2009 | NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | Cephalon | Phase 1/2 | Completed | Multiple Myeloma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00920855) |
| June 15, 2009 | NCT00920595 | Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors | Cephalon | Phase 1 | Completed | Solid Tumor | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00920595) |
| May 1, 2009 | NCT00891839 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | Cephalon | Phase 2 | Completed | Mantle Cell Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00891839) |
| April 3, 2009 | NCT00875264 | Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer | Cephalon | Phase 1 | Completed | Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00875264) |
| March 18, 2009 | NCT00863850 | Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy | Cephalon | Phase 1 | Completed | Malignancy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00863850) |
| February 12, 2009 | NCT00842829 | Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | Cephalon | Phase 4 | Terminated | Cancer Pain, Breakthrough Pain | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00842829) |
| January 19, 2009 | NCT00825227 | Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents | Cephalon | Phase 2 | Terminated | Fatigue, Chemotherapy Side Effects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00825227) |
| December 23, 2008 | NCT00813488 | Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain | Cephalon | Phase 3 | Completed | Chronic Pain | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00813488) |
| October 15, 2008 | NCT00772005 | Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia | Cephalon | Phase 2 | Completed | Schizophrenia | 287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00772005) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 19 |
| Phase 2/3 | 1 |
| Phase 3 | 39 |
| Phase 4 | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 63 |
| Terminated | 11 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Disorders of Excessive Somnolence | 13 |
| Neoplasms | 10 |
| Sleep Apnea, Obstructive | 8 |
| Pain | 8 |
| Narcolepsy | 7 |
| Breakthrough Pain | 6 |
| Lymphoma, Non-Hodgkin | 5 |
| Depression | 4 |
| Attention Deficit Disorder with Hyperactivity | 4 |
| Multiple Myeloma | 3 |
| Chronic Pain | 3 |
| Generalized Anxiety Disorder | 3 |
| Lymphoma, Mantle-Cell | 3 |
| Anxiety Disorders | 2 |
| Osteoarthritis | 2 |
| Sleep Apnea Syndromes | 2 |
| Burns | 2 |
| Anemia, Sickle Cell | 2 |
| Sleep Disorders, Circadian Rhythm | 2 |
| Chronobiology Disorders | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Cataplexy | 2 |
| Schizophrenia | 2 |
| Cancer Pain | 1 |
| Sleep Wake Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
- [Translation companies in the United States](https://specstream.ai/data/businesses/translation-companies/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Coffee shops in the United States](https://specstream.ai/data/businesses/coffee-shops/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
